Marinus Pharmaceuticals
US-based Marinus Pharmaceuticals develops and commercializes medical drugs for serious neurological and psychiatric disorders.
Founded
2003US-based Marinus Pharmaceuticals develops and commercializes medical drugs for serious neurological and psychiatric disorders.
Founded in Radnor, United States, Marinus Pharmaceuticals is dedicated to developing and commercializing medical drugs aimed at treating serious neurological and psychiatric disorders, including epilepsy, post-traumatic stress disorder, and fragile-X syndrome. The company’s core mission is to drastically improve the lives of patients affected by seizure disorders through mindful innovation and a compassionate approach to medicine.
Notable figures associated with Marinus Pharmaceuticals include a passionate team of experts committed to patient-centric innovation. The company has achieved significant milestones in the development of therapies for rare and challenging conditions, contributing to the broader medical community's understanding and treatment of these disorders. Marinus Pharmaceuticals' impact is evident in its dedication to transforming medicine and creating a better future for patients and their families.
Companies similar to Marinus Pharmaceuticals include Supernus Pharmaceuticals, Acadia Pharmaceuticals, Marius Pharmaceuticals and Harmony Biosciences.
Marinus Pharmaceuticals was founded in 2003.
Marinus Pharmaceuticals' headquarters is located in Radnor, PA, US.
Marinus Pharmaceuticals' most recent funding round was for $60M (USD) in November 2022.
As of Nov 7, 2022, Marinus Pharmaceuticals has disclosed funding of $406.9M (USD). Undisclosed round amounts are excluded.
Marinus Pharmaceuticals has 151 employees as of Feb 6, 2024.
Harmony Biosciences
